Shareholders Approve 1 Million Share Increase for Equity Incentive Plan
ASTH has more than doubled off its 52-week low of $18.08 on elevated volume (2.0× avg).
Summary
Astrana Health shareholders approved an amendment to its 2024 Equity Incentive Plan, increasing the shares reserved for issuance by 1 million, which represents approximately 1.8% potential dilution.
Key Events · Corporate Governance and Compliance · ASTH
-
Equity Incentive Plan Approved
Shareholders approved the Amended and Restated 2024 Equity Incentive Plan at the Annual Meeting held on June 10, 2026.
-
Share Reserve Increased
The number of shares reserved for issuance under the 2024 Plan was increased by 1,000,000 shares, representing approximately 1.8% potential dilution based on current outstanding shares.
-
Plan Term Extended
The term of the 2024 Plan was extended until March 24, 2036.
-
Routine Annual Meeting Approvals
Shareholders also elected nine directors, ratified the appointment of Ernst & Young LLP as the independent auditor, and approved executive compensation on an advisory basis.
Analysis · ASTH · Trade & Services
Astrana Health shareholders approved an amendment to the 2024 Equity Incentive Plan, increasing the shares reserved for issuance by 1 million. This authorization, representing approximately 1.8% potential dilution, provides the company with additional capacity for employee compensation and retention. While dilutive, such plans are a standard tool for motivating and retaining talent, especially for a company that has recently reported strong financial results and is trading near its 52-week high.
At the time of this filing, ASTH was trading at $38.73 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $18.08 to $39.93. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.